Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | CD69 | Q07108 | 4/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | CASP1 | P29466 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321504 | 0.87 | L3MBTL1 (0.56) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL5846509 | 0.87 | KMT2A (0.53) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL6744642 | 0.86 | SMN1; SMN2 (0.70) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL7752635 | 0.85 | FABP4 (0.60) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL340762 | 0.84 | L3MBTL1 (0.80) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL29682135 | 0.84 | L3MBTL1 (0.80) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL31552456 | 0.83 | SMN1; SMN2 (0.71) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| Ammonia Solution, Strong SCHEMBL28240461 | 0.82 | L3MBTL1 (0.77) | KDM4EALDH1A1HPGDTDP1L3MBTL1 | |
| SCHEMBL8414412 | 0.81 | PTGDR2 (0.57) | KMT2AKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL5379717 | 0.81 | L3MBTL1 (0.63) | KMT2AKDM4EALDH1A1HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2175863-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | Eastern Virginia Medical School (US) | 2010-04-21 | — | — | EP | claimed |
| WO-2009009625-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2009-01-15 | — | — | WO | claimed |
| US-20230173077-A1 | FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS | AJK Biopharmaceutical, LLC | 2023-06-08 | — | — | US | disclosed |
| WO-2021222807-A1 | FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS | AJK PHARMACEUTICAL LLC (US) | 2021-11-04 | — | — | WO | disclosed |
| US-9738678-B2 | Substituted nucleoside derivatives with antiviral and antimicrobial properties | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160311843-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2016-10-27 | — | — | US | disclosed |
| US-9296776-B2 | Substituted nucleoside derivatives with antiviral and antimicrobial properties | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2016-03-29 | — | — | US | disclosed |
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2175863-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | Eastern Virginia Medical School (US) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009009625-A2 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | EASTERN VIRGINIA MEDICAL SCHOOL (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230173077-A1 | FATTY ACYL AND FATTY ETHER CONJUGATES OF REMDESIVIR AND ITS ACTIVE METABOLITES AS ANTIVIRALS | ELOVL6, FADS2, FASN | KMT2A 653/4885KDM4E 348/4885ALDH1A1 680/4885 |
| US-20110039798-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | KMT2A 3954/4885KDM4E 3614/4885ALDH1A1 1864/4885 |
| US-20160311843-A1 | SUBSTITUTED NUCLEOSIDE DERIVATIVES WITH ANTIVIRAL AND ANTIMICROBIAL PROPERTIES | SAMHD1, TLR3, MAVS | KMT2A 3954/4885KDM4E 3614/4885ALDH1A1 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.